ARTHUR-D-LITTLE
23.9.2020 10:02:14 CEST | Business Wire | Press release
Following the completion of its ninth Partners’ and Shareholders’ Meeting since becoming a private partnership again in 2011, Arthur D. Little (ADL) today announces the new members of its Board of Directors. The Shareholders’ Meeting also re-elected Ignacio García Alves to serve a new tenure of three years as Chief Executive Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005336/en/
The results of the 2020 digital elections for the Board of Directors, with each member to serve a tenure of three years, were as follows:
- Ignacio García Alves (Chairman)
- Rodolfo Guzman
- Yusuke Harada
- Thomas Kuruvilla
- Bernd Schreiber
- Ulrica Sehlstedt
- Nick White.
Held this year as a digital event that included over 100 participants, the Partners’ and Shareholders’ Meeting was an opportunity to celebrate the company’s ongoing success and resilience in the face of an exceptionally challenging year 2020 for the world.
Over the past five years, ADL has doubled in size, expanding its already-global geographic scope with 15 new offices, and adding 19 newly promoted and newly recruited Partners just this year. While pursuing a dynamic, sustainable and profitable growth path, the company has continuously transformed itself. ADL plans to accelerate its development, with substantial investments in people, new leading-edge offerings and digital, plus an increased focus on its unique “open consulting” approach, with the company having been widely recognized for its ability to combine a network of global experts and partner firms, with its own internal strengths.
Ignacio García Alves, Chairman and Chief Executive Officer of Arthur D. Little , comments: “I am very thankful for this renewed expression of confidence, and I am determined to continue the extraordinary development of Arthur D. Little during this new mandate. I would also like to congratulate all new Board members as they take up their roles. I am confident they will be a great support and a vital driving force in aggressively and sustainably developing our company.
“Since our management buyout, we have made continuous and impressive progress, not to mention the strong resilience we have demonstrated during the COVID-19 crisis. I am truly inspired by the sheer energy and winning spirit of our teams. We are now entering a new chapter, and have ambitious plans to invest in the future by building on recent acquisitions (Presans and Cutter Consortium) and driving value through innovative offerings.
“Our commitment remains unchanged: we are here to help our clients, and the communities they serve, overcome today’s most pressing challenges and seize tomorrow’s most promising opportunities.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005336/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
90% of IT Leaders See Gaps in AI Threat Readiness, Lenovo Brings Single Point of Accountability to Cyber Resiliency30.6.2026 15:00:00 CEST | Press release
New end-to-end resilience and managed security offerings help organizations reduce security complexity, cut system downtime by up to 50%, and lower remediation costs by up to 40% by bringing devices, security technologies, expert services, and ecosystem partners together under a single operational model As organizations accelerate AI adoption and digital workplace transformation, many are finding that cyber resilience is undermined not by a lack of security tools, but by growing operational complexity and threat sophistication. According to recent research, 90% of IT leaders acknowledge gaps in their ability to defend against AI-driven threats. While security investments continue to grow, many organizations face a different challenge: fragmented accountability. Security operations remain highly distributed and siloed, making it increasingly difficult to coordinate response efforts, maintain end-to-end business continuity, and recover quickly when incidents occur. To help organizations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom